Literature DB >> 30569372

Dialysis independence following single-agent daratumumab in refractory myeloma with renal failure.

Elizabeth Smyth1, Siobhan Glavey1, Dario Melotti1, Patrick Thornton1, Jeremy Sargent1, Peter Conlon2, Philip Murphy1, John Quinn3.   

Abstract

Entities:  

Keywords:  Daratumumab; Dialysis independence; Dialysis-dependant renal failure; Multiple myeloma

Year:  2018        PMID： 30569372     DOI： 10.1007/s11845-018-1951-6

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN： 0021-1265            Impact factor:   1.568


× No keyword cloud information.
  9 in total

1.  Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.

Authors:  Colin A Hutchison; Paul Cockwell; Stephanie Stringer; Arthur Bradwell; Mark Cook; Morie A Gertz; Angela Dispenzieri; Jeffrey L Winters; Shaji Kumar; S Vincent Rajkumar; Robert A Kyle; Nelson Leung
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

2.  A population-based study of the impact of dialysis on mortality in multiple myeloma.

Authors:  Felicity Evison; Jason Sangha; Punit Yadav; Yu Sandar Aung; Adnan Sharif; Jennifer A Pinney; Mark T Drayson; Mark Cook; Paul Cockwell
Journal:  Br J Haematol       Date:  2016-10-21       Impact factor: 6.998

3.  Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma.

Authors:  Serena Rocchi; Paola Tacchetti; Lucia Pantani; Katia Mancuso; Beatrice Zannetti; Michele Cavo; Elena Zamagni
Journal:  Haematologica       Date:  2018-04-05       Impact factor: 9.941

4.  Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

Authors:  Asher A Chanan-Khan; Jonathan L Kaufman; Jayesh Mehta; Paul G Richardson; Kena C Miller; Sagar Lonial; Nikhil C Munshi; Robert Schlossman; Joseph Tariman; Seema Singhal
Journal:  Blood       Date:  2006-11-30       Impact factor: 22.113

5.  Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.

Authors:  Meletios Dimopoulos; Katja Weisel; Niels W C J van de Donk; Karthik Ramasamy; Barbara Gamberi; Matthew Streetly; Massimo Offidani; Frank Bridoux; Javier de la Rubia; Maria-Victoria Mateos; Antonio Ardizzoia; Elisabeth Kueenburg; Shona Collins; Antonia Di Micco; Barbara Rosettani; Yan Li; Pamela Bacon; Pieter Sonneveld
Journal:  J Clin Oncol       Date:  2018-02-02       Impact factor: 44.544

6.  Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre.

Authors:  Richard J Haynes; Simon Read; Graham P Collins; Sarah C Darby; Christopher G Winearls
Journal:  Nephrol Dial Transplant       Date:  2009-09-19       Impact factor: 5.992

7.  Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

Authors:  Henk M Lokhorst; Torben Plesner; Jacob P Laubach; Hareth Nahi; Peter Gimsing; Markus Hansson; Monique C Minnema; Ulrik Lassen; Jakub Krejcik; Antonio Palumbo; Niels W C J van de Donk; Tahamtan Ahmadi; Imran Khan; Clarissa M Uhlar; Jianping Wang; A Kate Sasser; Nedjad Losic; Steen Lisby; Linda Basse; Nikolai Brun; Paul G Richardson
Journal:  N Engl J Med       Date:  2015-08-26       Impact factor: 91.245

8.  Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.

Authors:  Punit Yadav; Colin A Hutchison; Kolitha Basnayake; Stephanie Stringer; Mark Jesky; Lesley Fifer; Kym Snell; Jennifer Pinney; Mark T Drayson; Mark Cook; Paul Cockwell
Journal:  Eur J Haematol       Date:  2015-09-16       Impact factor: 2.997

9.  Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit.

Authors:  M A Dimopoulos; M Roussou; M Gavriatopoulou; D Fotiou; D C Ziogas; M Migkou; I Panagiotidis; E Eleutherakis-Papaiakovou; N Kanellias; E Psimenou; S Marinaki; D Bacharaki; D Mparmparoussi; C Matsouka; S Giannouli; E Terpos; E Kastritis
Journal:  Blood Cancer J       Date:  2017-06-16       Impact factor: 11.037
  9 in total
  6 in total

1.  Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma.

Authors:  Shinichi Mizuno; Chigusa Kitayama; Shigeto Mashiko; Satoru Sanada
Journal:  CEN Case Rep       Date:  2021-11-24

Review 2.  An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment.

Authors:  Meletios A Dimopoulos; Joseph Mikhael; Evangelos Terpos; Xavier Leleu; Philippe Moreau; Joan Bladé; Jin Seok Kim; Keith Stockerl-Goldstein; Paul G Richardson
Journal:  Ther Adv Hematol       Date:  2022-04-02

3.  Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.

Authors:  Marcelo Capra; Thomas Martin; Philippe Moreau; Ross Baker; Ludek Pour; Chang-Ki Min; Xavier Leleu; Mohamad Mohty; Marta Reinoso Segura; Mehmet Turgut; Richard LeBlanc; Marie-Laure Risse; Laure Malinge; Sandrine Schwab; Meletios Dimopoulos
Journal:  Haematologica       Date:  2022-06-01       Impact factor: 11.047

4.  Efficacy of Immunomodulatory Drugs in Combination With Dexamethasone in Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits.

Authors:  Houan Zhou; Manna Li; Caihong Zeng; Zhaohong Chen; Ti Zhang; Zhen Cheng
Journal:  Kidney Int Rep       Date:  2022-08-08

5.  Daratumumab in dialysis-dependent multiple myeloma.

Authors:  Preethi Jeyaraman; Alka Bhasin; Nitin Dayal; Sangeeta Pathak; Rahul Naithani
Journal:  Blood Res       Date:  2020-03-30

6.  Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma.

Authors:  Masuho Saburi; Masao Ogata; Yasuhiro Soga; Yoshiyuki Kondo; Ryo Kurimoto; Kazuhito Itani; Kazuhiro Kohno; Hiroki Uchida; Toshiyuki Nakayama
Journal:  J Clin Exp Hematop       Date:  2020
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.